Idarucizumab for dabigatran reversal -full cohort analysis

New England Journal of Medicine

Volumn 377, Issue 5, 2017, Pages 431-441

  Pollack, Charles V ^a   Reilly, Paul A ^b   Van Ryn, Joanne ^c   Eikelboom, John W ^c   Glund, Stephan ^c   Bernstein, Richard A ^e   Dubiel, Robert ^b   Huisman, Menno V ^b   Hylek, Elaine M ^f,i   Kam, Chak Wah ^g,k   Kamphuisen, Pieter W ^h   Kreuzer, J G ^j   Levy, Jerrold H ^k   Royle, Gordon ^l   Sellke, Frank W ^l   Stangier, Joachim ^c   Steiner, Thorsten ^c,d   Verhamme, Peter ^l   Wang, Bushi ^a   Young, Laura ^a   Weitz, Jeffrey I ^a   more..

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e MCMASTER UNIVERSITY   (Canada)

^f NORTHWESTERN UNIVERSITY   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h TERGOOI HOSPITAL   (Netherlands)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j TUEN MUN HOSPITAL   (Hong Kong)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF AUCKLAND   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; IDARUCIZUMAB; ANTIBODY; ANTICOAGULANT AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; COHORT ANALYSIS; DELIRIUM; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEMOSTASIS; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; SEPTIC SHOCK; THROMBIN TIME; UNCONSCIOUSNESS; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG HYPERSENSITIVITY; HEMORRHAGE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; PROSPECTIVE STUDY; THROMBOSIS; TIME FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; BLOOD COAGULATION; DABIGATRAN; DRUG HYPERSENSITIVITY; FEMALE; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBIN TIME; THROMBOSIS; TIME FACTORS;

EID: 85026815616     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1707278     Document Type: Article

References (21)

1. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-62.
2. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511-20.
3. Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114: 198-205.
4. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-8.
5. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95.
6. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-43.
7. Schulman S, Anger U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-4.
8. MedDRA. Introductory guide: Med-DRA version 18.0. March 2015 (https://www .meddra .org/sites/default/files/guidance/file/intguide-18-0-english .pdf).
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
10. Glund S, Stangier J, van Ryn J, et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 2017; 56: 41-54.
11. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-51.
12. Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): A randomised trial. Lancet Neurol 2016; 15: 566-73.
13. Lopes RD, Guimars PO, Kolls BJ, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood 2017; 129: 2980-7.
14. Mehta KD, Patel S, Patel K, Wang H, Parikh RA, Smith RE. Trends of inpatient venous thromboembolism in United States before and after Surgeon General's call to action. Blood 2016; 128: 1177. abstract.
15. Heit JA, Crusan DJ, Ashrani AA, Petterson TM, Bailey KR. Effect of near-universal hospitalization-based prophylaxis on annual number of venous thromboembolism events in the US. Blood 2017 May 8 (Epub ahead of print).
16. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasmacontrolled, phase IIIb study. Circulation 2013; 128: 1234-43.
17. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: A phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385: 2077-87.
18. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131-41.
19. Connolly SJ, Gibson CM, Crowther M. Andexanet alfa for factor Xa inhibitor reversal. N Engl J Med 2016; 375: 2499-500.
20. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-507.
21. Vosko MR, Bocksrucker C, Drwila R, et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-Treated patients: A series of 11 cases. J Thromb Thrombolysis 2017; 43: 306-17.